Evaluation of Checkpoint Inhibitor Therapies using a Mixed Lymphocyte Reaction (MLR) Assay

Immune checkpoints are signalling molecules that control the synapse between T cells and antigen presenting cells (APCs). Checkpoint inhibitor therapies target and inhibit the signals that ‘switch off’ T cells, leading to an upregulation of T cell activation and tumour cell killing. The mixed lymphocyte reaction (MLR) mimics the T cell and APC synapse by co-culturing immune cells from two individuals. MLR is used as a model to explore the effects of checkpoint inhibitor drugs in vitro; facilitating drug discovery processes and biological research applications. 

What you will learn from this webinar:

• How the iQue® Advanced Flow Cytometry Platform and associated reagent kits can be used to quantify T cell response in MLR.
• The use of the iQue® MLR assay to generate pharmacological outputs for checkpoint inhibitor induced T cell activation.
• The impact of checkpoint inhibitor therapeutics on inflammatory cytokine release.